Autoradiography. For autoradiographic localization of [3H]BK receptor binding, guinea pigs were perfused through the heart with 500 ml of a mixture of equal parts of isotonic phosphate-buffered saline (pH 7.4) and 10%o (wt/vol) sucrose. After perfusion, the tissues were removed, embedded in homogenized calf cortex, and frozen on dry ice. Canine tissues were removed without perfusion and immersed in chilled perfusion medium for 20 min, then mounted and frozen as described. Ten-micrometer sections were cut in a cryostat at -12°C, thaw-mounted onto chrome alum/gelatin-coated microscope slides, and stored frozen at -20°C.When ready for use, the slides were warmed to room temperature, incubated for 120 min at 4°C in medium containing 20 mM 2-{[tris(hydroxymethyl)methyl]amino}ethane sulfonic acid (Tes) (pH 6.8), 1 mM 1,10-phenanthroline, 0.2% bovine serum albumin (protease free), 1 mM dithiothreitol, bacitracin (140 ,ug/ml), 0.1 mM SQ20,881, 300 mM sucrose, and 0.5 nM [3H]BK (52 Ci/mmol; 1 Ci = 37 GBq).Blanks were incubated in the same medium with 1 ,uM unlabeled BK or Lys-BK.After incubation, the tissue sections were washed in a solution of 25 mM Tes (pH 6.8) and 10% (vol/vol) sucrose for two 10-min periods at 4°C, dried rapidly under cold dry air, and apposed to either NTB-3 emulsion-coated coverslips or LKB Ultrafilm for 1 month. After exposure, the coverslip/slide or Ultrafilm was developed, and the tissue was stained with cresyl violet.Isolated Tissues. Smooth muscle effects of the BK analogs were determined on the isolated rat uterus and isolated guinea pig ileum by standard methods (10). BK analogs were incubated with the preparation for 30 sec before adding an ED50 dose of BK. BK analogs that decreased BK were then examined in detail to determine pA2 values for antagonism (pA2 is the negative log of the antagonist concentration that causes a 2-fold shift in the agonist dose-response curve) (11). Dose-response curves were determined for analogs that produced contractions at 10 uM.BK-Induced Vascular Pain. Male Sprague-Dawley rats (200-300 g) (Charles River Breeding Laboratories) were housed five per cage with constant access to food and water with a 12-hr light-dark cycle (7 a.m.-7 p.m.). Rats received an indwelling carotid artery cannula routed subcutaneously to exit behind the head. One to 3 days following surgery, the cannula was connected through tubing to a remote syringe allowing intraarterial injections while the rats were conscious and freely moving. In preliminary experiments, BK at 2 nmol/kg caused stereotypic flexion of the right forelimb and dextrorotation of the head in essentially 100% of the rats tested. Rats that displayed this BK response were injected 5 min later, through the same arterial cannula, with BK and a BK antagonist at 2, 20, or 200 nmol/kg.
Bradykinin and its active metabolites are produced at the sites of their actions by kallikreins. They potently elicit a variety of biological effects: hypotension, bronchoconstriction, gut and uterine contraction, epithelial secretion in airway, gut, and exocrine glands, vascular permeability, pain, connective tissue proliferation, and eicosanoid formation. These effects are mediated by at least two broad classes of receptors. The most common is the B2 subtype. The Stewart and Vavrek peptides characterized by a DPhe7 substitution have provided powerful tools for study of bradykinin's actions by competitively and specifically blocking bradykinin B2 receptors. The significance of kinins in certain human diseases is being explored using these new tools and potential therapeutic agents. At present, human clinical trials are underway to test the usefulness of bradykinin receptor antagonists in the symptoms of the common cold and in the pain associated with severe burns. Trials for use in asthma will be initiated in 1990.
Bradykinin and its active metabolites, produced by kallikreins at their sites of action, potently elicit a variety of biological effects: hypotension, bronchoconstriction, gut and uterine contraction, epithelial secretion in airway, gut, and exocrine glands, vascular permeability, pain, connective tissue proliferation, cytokine release, and eicosanoid formation. These effects are mediated by at least two broad classes of receptors. The most common is the B2 subtype. The availability of competitive antagonists of B2 receptors has provided powerful tools for the study of bradykinin's actions. The significance of kinins in certain human diseases is being explored by using these agents as potential therapeutic agents. Human clinical trials are under way to test the usefulness of bradykinin receptor antagonists to treat symptoms of the common cold and the pain associated with severe burns. Trials are also being comtemplated for use in treatment of asthma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.